In fact, cancer cells may acquire resistance to EGFR inhibitors by increasing the expression and/or the activity of several signalling proteins downstream to EGFR, including pMAPK, pAkt and VEGF, which represent the major escape pathways for EGFR inhibition (Ciardiello et al, 2004; Zhang et al, 2004; Morgillo and Lee, 2005). Here, EGFR is linked to cancer.